XTRA:MRK Earnings and Revenue History March 14th 2025 How Do Unusual Items Influence Profit? For anyone who wants to understand Merck KGaA's profit beyond the statutory numbers, i ...
Celonic Integrates Merck’s Breez Micro-Bioreactor Platform Into Its Process Development Operations
The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...
In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of ...
SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...
ShareIn commemoration of the 2025 International Women’s Day, Merck Foundation, the philanthropic arm of Merck KGaA Germany and African First Ladies have reaffirmed their commitment to empowering women ...
In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
The Federal Circuit reinstated a challenge of a Merck KGaA unit’s pigment patent by South Korea-based CQV Co. on Monday, ...
Clinical Trials Arena on MSN6d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but ...
Pharmaceutical Technology on MSN7d
Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talksWhile the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.
Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback